ReviewFrontiers in pharmacology2026
Epigenetic and mitoepigenetic regulation in cancer and therapeutic perspectives.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic modifications on nuclear and mitochondrial DNA constitute key regulatory layers influencing the transcriptional, metabolic, and phenotypic adaptability of cancer cells. The canonical principles of epigenetic control encompass DNA methylation, histone modification, and non-coding RNA-mediated regulation, which collectively contribute to the silencing of tumor suppressor genes, the activation of oncogenes, and chromatin remodeling. Therefore, epigenetic drugs (epi-drugs) are of great interest in the development of new-generation therapeutics and holistic treatment approaches. Accordingly, this work presents a narrative review that integrates current evidence on the molecular mechanisms, therapeutic developments, and translational relevance of epigenetic and mitoepigenetic regulation in cancer. RNA-mediated regulation collectively contributes to the silencing of tumor suppressor genes and to the activation of oncogenes. The field of mitoepigenetics encompasses mitochondrial DNA (mtDNA) methylation, RNA modifications, and post-translational regulation of mitochondrial proteins such as TFAM, DNMT1, and sirtuins, which influence oxidative phosphorylation, redox balance, and apoptotic pathways, thereby affecting tumor initiation, progression, and treatment response. Recent advances in epigenetic drug development include FDA-approved DNMT and HDAC inhibitors and newer agents targeting EZH2, IDH1/2, and DOT1L, which broaden the scope of precision oncology. In addition, modulation of mitochondrial epigenetic mechanisms has been identified as a potential approach for addressing metabolic reprogramming and therapeutic resistance in cancer. The convergence of nuclear and mitochondrial regulatory frameworks reveals the critical need for biomarker-informed, combinatory, and organelle-targeted therapeutic approaches to sustain treatment efficacy. Comprehensive characterization and pharmacological targeting of epigenetic and mitoepigenetic networks provide a structured basis for developing personalized and metabolism-informed interventions in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.